Pharming, Santarus submit angioedema drug for FDA approval

04/18/2013 | Pharmaceutical Business Review Online

Pharming Group and Santarus have filed a biologics license application with the FDA for approval to use Ruconest, a recombinant human C1 esterase inhibitor, as a treatment for acute angioedema attacks in people with hereditary angioedema. Santarus holds the right to market the drug in North America.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC